KLRS · Insider Trading
Kalaris Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by KLRS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-28 | Amy O'Leary Vandekop | VP, Corporate Controller | A | +10,000 deriv. | — |
| 2026-08-03 | Laurie Keating | Director | A | +18,000 deriv. | — |
| 2026-07-20 | Liisa Ann Bayko | Chief Financial Officer | A | +220,000 deriv. | — |
| 2026-06-04 | Leone D Patterson | Director | A | +9,000 deriv. | — |
| 2026-06-04 | Morana Jovan-Embiricos | Director | A | +9,000 deriv. | — |
| 2026-06-04 | Anthony P Adamis | Director | A | +9,000 deriv. | — |
| 2026-06-04 | David Hallal | Director | A | +9,000 deriv. | — |
| 2026-06-04 | Michael Dybbs | Director | A | +9,000 deriv. | — |
| 2026-06-04 | Srinivas Akkaraju | Director | A | +9,000 deriv. | — |
| 2026-06-04 | Napoleone Ferrara | Director | A | +9,000 deriv. | — |
| 2026-05-22 | Srinivas Akkaraju | Director | MIXED | +196,802 | +$1.18M |
| 2026-03-23 | Brett R Hagen | Chief Accounting Officer | Sell | −1,915 | −$12.87K |
| 2026-03-20 | Matthew Gall | Chief Financial Officer | A | +95,000 deriv. | — |
| 2026-03-20 | Andrew Oxtoby | See Remarks | A | +222,000 deriv. | — |
| 2026-03-20 | Matthew Feinsod | Chief Medical Officer | A | +135,000 deriv. | — |
| 2026-02-17 | Samsara BioCapital, L.P. | 10%+ Owner | Buy | +479,847 | +$5.00M |
| 2025-12-22 | Samsara Opportunity Fund, L.P. | 10%+ Owner | A | +1,500,000 | +$15.00M |
| 2025-11-03 | Matthew Gall | Chief Financial Officer | A | +235,000 deriv. | — |
| 2025-04-11 | Leone D Patterson | Director | A | +18,000 deriv. | — |
| 2025-04-11 | Brett R Hagen | Chief Accounting Officer | A | +50,262 deriv. | — |
| 2025-04-11 | Anthony P Adamis | Director | A | +18,000 deriv. | — |
| 2025-04-11 | Michael Dybbs | Director | A | +18,000 deriv. | — |
| 2025-04-11 | Andrew Oxtoby | See Remarks | A | +287,000 deriv. | — |
| 2025-04-11 | Matthew Feinsod | Chief Medical Officer | A | +171,551 deriv. | — |
| 2025-04-11 | Morana Jovan-Embiricos | Director | A | +18,000 deriv. | — |
| 2025-04-11 | Samir Chandrakant Patel | Director | A | +18,000 deriv. | — |
| 2025-04-11 | Napoleone Ferrara | Director | A | +18,000 deriv. | — |
| 2025-04-11 | David Hallal | Director | A | +18,000 deriv. | — |
| 2025-04-11 | Srinivas Akkaraju | Director | A | +18,000 deriv. | — |
| 2025-03-27 | Brett R Hagen | Chief Accounting Officer | Sell | −907 | −$8.14K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Samsara BioCapital, L.P. | 10%+ Owner | 1,979,847 | $4.71M |
| Samsara Opportunity Fund, L.P. | 10%+ Owner | 1,500,000 | $3.57M |
| Srinivas Akkaraju | Director | 19,408 | $46.19K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KLRS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.